Zacks: Analysts Expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Will Announce Earnings of $0.55 Per Share

Equities analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) to report earnings of $0.55 per share for the current fiscal quarter, Zacks Investment Research reports. Eleven analysts have provided estimates for Neurocrine Biosciences’ earnings, with the highest EPS estimate coming in at $0.82 and the lowest estimate coming in at $0.33. Neurocrine Biosciences reported earnings of $0.43 per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 27.9%. The firm is scheduled to issue its next earnings results on Monday, January 1st.

According to Zacks, analysts expect that Neurocrine Biosciences will report full year earnings of $1.91 per share for the current year, with EPS estimates ranging from $1.55 to $2.35. For the next fiscal year, analysts anticipate that the business will post earnings of $3.30 per share, with EPS estimates ranging from $2.25 to $5.05. Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Neurocrine Biosciences.

Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) last issued its quarterly earnings results on Wednesday, May 4th. The company reported $0.14 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.33 by ($0.19). Neurocrine Biosciences had a return on equity of 5.30% and a net margin of 5.91%. The business had revenue of $310.60 million for the quarter, compared to the consensus estimate of $304.07 million. During the same period in the prior year, the business posted $0.33 earnings per share. Neurocrine Biosciences’s revenue was up 31.3% on a year-over-year basis.

Several research firms have commented on NBIX. HC Wainwright restated a “buy” rating and set a $140.00 price objective on shares of Neurocrine Biosciences in a report on Monday, February 14th. Morgan Stanley lifted their price target on Neurocrine Biosciences from $95.00 to $100.00 and gave the company an “equal weight” rating in a report on Monday, February 14th. Jefferies Financial Group downgraded Neurocrine Biosciences to a “hold” rating and set a $94.00 target price on the stock. in a research note on Thursday, March 3rd. The Goldman Sachs Group upgraded Neurocrine Biosciences from a “neutral” rating to a “buy” rating and set a $115.00 target price on the stock in a research note on Thursday, February 24th. Finally, Barclays boosted their target price on Neurocrine Biosciences from $100.00 to $110.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 12th. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and ten have issued a buy rating to the company’s stock. Based on data from MarketBeat, Neurocrine Biosciences presently has an average rating of “Hold” and an average target price of $112.13.

Shares of NBIX stock traded up $3.26 on Friday, reaching $93.10. 781,007 shares of the company’s stock were exchanged, compared to its average volume of 902,389. The company’s fifty day simple moving average is $91.49 and its 200 day simple moving average is $86.59. The stock has a market capitalization of $8.90 billion, a PE ratio of 129.31 and a beta of 0.70. Neurocrine Biosciences has a 52 week low of $71.88 and a 52 week high of $108.01. The company has a current ratio of 4.02, a quick ratio of 3.90 and a debt-to-equity ratio of 0.27.

In other Neurocrine Biosciences news, Director William H. Rastetter sold 10,728 shares of the company’s stock in a transaction on Friday, April 1st. The stock was sold at an average price of $94.93, for a total transaction of $1,018,409.04. Following the transaction, the director now directly owns 34,022 shares in the company, valued at $3,229,708.46. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Richard F. Pops sold 15,000 shares of the company’s stock in a transaction on Monday, May 9th. The stock was sold at an average price of $76.30, for a total value of $1,144,500.00. Following the transaction, the director now owns 29,512 shares in the company, valued at $2,251,765.60. The disclosure for this sale can be found here. Insiders sold 49,483 shares of company stock valued at $4,386,457 over the last 90 days. Company insiders own 4.40% of the company’s stock.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Two Sigma Advisers LP acquired a new stake in shares of Neurocrine Biosciences in the third quarter valued at $1,618,000. Cibc World Markets Corp purchased a new position in shares of Neurocrine Biosciences during the fourth quarter worth about $4,259,000. Nisa Investment Advisors LLC grew its holdings in shares of Neurocrine Biosciences by 677.1% during the fourth quarter. Nisa Investment Advisors LLC now owns 31,754 shares of the company’s stock worth $2,509,000 after purchasing an additional 27,668 shares during the last quarter. Toronto Dominion Bank grew its holdings in shares of Neurocrine Biosciences by 301.9% during the fourth quarter. Toronto Dominion Bank now owns 53,661 shares of the company’s stock worth $4,570,000 after buying an additional 40,310 shares during the last quarter. Finally, GW&K Investment Management LLC grew its holdings in shares of Neurocrine Biosciences by 3.3% during the fourth quarter. GW&K Investment Management LLC now owns 458,615 shares of the company’s stock worth $39,061,000 after buying an additional 14,733 shares during the last quarter. Institutional investors and hedge funds own 93.21% of the company’s stock.

About Neurocrine Biosciences (Get Rating)

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas.

Featured Articles